Merck - Ridgeback's COVID-19 Antiviral Shows Rapid Elimination Of Infectious SARS-CoV-2 Than Placebo

  • Merck & Co Inc MRK and Ridgeback Biotherapeutics will present data evaluating Lagevrio (molnupiravir), an oral COVID-19 antiviral, at the 2022 European Congress of Clinical Microbiology & Infectious Diseases.
  • The presentation includes final analyses evaluating virologic outcomes throughout and following a five-day course of molnupiravir as part of the Phase 3 MOVe-OUT trial.
  • At Day 3 of treatment, among patients with the infectious virus at baseline, infectious SARS-CoV-2 was detected in 0.0% (n=0/92) of patients who received molnupiravir, compared with 21.8% (n=20/96) of patients who received placebo. 
  • At Day 5, infectious virus was detected in 0.0% (n=0/91) of patients in the molnupiravir arm compared with 2.2% (n=2/89) in the placebo arm. 
  • Related: WHO Conditionally Recommends Merck's COVID-19 Antiviral Pill For High-Risk Patients.
  • At Day 10, no infectious virus was detected in either arm for patients with the contagious virus at baseline. 
  • Molnupiravir is being evaluated for post-exposure prophylaxis in the MOVe-AHEAD Phase 3 study evaluating the efficacy and safety of molnupiravir in preventing the spread of COVID-19 within households.
  • Price Action: MRK shares are up 0.55% at $82.50 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 CoronavirusPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!